NewAmsterdam Pharma Company (NAMS) AI Stock Analysis

• Market Cap: $1.92B
• Dividend Yield: N/A
• Average Volume (3M): 1.08M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.78
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 68
• Sector: Healthcare
• Sector Strength: 69
• Industry: Biotechnology
• EPS (TTM): -2.60
• Shares Outstanding: 109,817,810
• 10 Day Avg. Volume: 508,344
• 30 Day Avg. Volume: 1,075,374
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 79.94
• Price to Cash Flow (P/CF): -52.40
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $43.00
• Price Target Upside: 145.43% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

NewAmsterdam Pharma's stock score reflects challenges with financial performance due to ongoing operational losses typical of biotech firms. Despite a strong balance sheet, the lack of profitability and negative cash flow are significant concerns. The technical analysis indicates bearish sentiment, and the valuation is weak due to the negative P/E ratio. However, the recent corporate event, namely the appointment of an experienced board member, provides a positive outlook for future growth and potential stock recovery.

Positive Factors

Financial Position

The company reported a strong cash position of $834.2M, which is believed to amply fund operations through the CVOT top-line in 2H26 and drive launch prep for obi in the US.

Regulatory Developments

A new executive order could extend small molecule exclusivity from 9 to 13 years, aligning it with biologics, which would particularly benefit NAMS by delaying Medicare price negotiations.

Strategic Interest

NAMS could see significant strategic interest from pharma in the future, driven by factors like patent exclusivity until 2043 and potential for mass market combinations.

Negative Factors

Data Catalyst Timeline

The next significant data catalyst is not expected until PREVAIL CVOT.

Market Comparison

The market opportunity for NewAmsterdam is not seen as being meaningfully altered by AstraZeneca's results.

Research and Development Costs

Price target moves to $42 from $46 to reflect model updates with higher than expected R&D in 2025.

NewAmsterdam Pharma Company Business Overview & Revenue Model

Company Description

NewAmsterdam Pharma Company (NAMS) is a clinical-stage biopharmaceutical company dedicated to the research, development, and commercialization of transformative therapies. The company primarily focuses on addressing cardiovascular and metabolic diseases, with its flagship product being an innovative oral small molecule therapy aimed at reducing cardiovascular risk in patients with high cholesterol levels. Leveraging cutting-edge science and strategic partnerships, NAMS seeks to bring novel treatment options to patients worldwide.

How the Company Makes Money

NewAmsterdam Pharma Company (NAMS) generates revenue through a combination of product sales, strategic partnerships, and licensing agreements. The company's primary revenue stream is anticipated to come from the commercialization of its lead product candidate, which is currently in clinical trials. Upon successful approval by regulatory authorities, NAMS plans to market and sell this therapy to healthcare providers and patients, thereby generating sales revenue. Additionally, NAMS engages in partnerships with other pharmaceutical companies and research institutions, which may involve collaborative research and development efforts, resulting in milestone payments and royalties. These significant partnerships not only provide financial support but also enhance the company's access to cutting-edge research and development capabilities, further contributing to its revenue potential.

NewAmsterdam Pharma Company Financial Statement Overview

Summary

NewAmsterdam Pharma exhibits typical characteristics of a biotech firm with high R&D expenses leading to operational losses. While revenue growth is promising, profitability remains a challenge. The balance sheet is strong with low leverage, providing stability. Cash flows are negative, but capital raising efforts support liquidity. The company must focus on achieving profitability to ensure long-term sustainability.

Income Statement

The company's revenue has shown significant volatility with periods of growth and decline. The gross profit margin is 100% due to no cost of goods sold, but the net profit margin is low due to high operating expenses. EBIT and EBITDA margins are negative, indicating operational challenges. Revenue growth from 2023 to 2024 is strong, but the company has not achieved profitability.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 87.6%, indicating low leverage. Debt-to-equity is minimal at 0.06, suggesting low financial risk. However, the company has reported consecutive net losses, impacting return on equity, which remains negative.

Cash Flow

Operating cash flow is consistently negative, highlighting cash burn issues typical in the biotechnology industry. Free cash flow growth is negative, indicating increased outflows. However, ample financing cash flow suggests the company is able to raise capital successfully, mitigating immediate liquidity concerns.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
45.56M	12.76M	95.91M	0.00	0.00
	Gross Profit
45.56M	12.76M	95.91M	0.00	0.00
	EBIT
-176.29M	-165.73M	-3.32M	-30.73M	-5.43M
	EBITDA
-241.49M	-176.86M	-3.31M	-30.73M	-5.43M
	Net Income Common Stockholders
-241.60M	-176.94M	-21.14M	-36.71M	-5.75M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
834.19M	340.45M	438.52M	53.09M	7.86M
	Total Assets
864.62M	347.10M	531.58M	59.78M	9.23M
	Total Debt
448.00K	60.00K	118.00K	164.00K	11.65M
	Net Debt
-771.29M	-340.39M	-438.40M	-52.93M	3.79M
	Total Liabilities
107.12M	58.70M	47.06M	9.99M	12.81M
	Stockholders Equity
757.50M	288.39M	484.52M	49.79M	-3.58M
Cash Flow		Free Cash Flow
-159.24M	-141.24M	7.96M	-25.18M	-5.98M
	Operating Cash Flow
-158.56M	-141.22M	7.97M	-25.16M	-5.97M
	Investing Cash Flow
-62.85M	-24.00K	715.00K	-20.00K	-13.00K
	Financing Cash Flow
659.51M	8.91M	375.18M	68.99M	11.32M

NewAmsterdam Pharma Company Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 17.52
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAMS, the sentiment is Negative. The current price of 17.52 is above the 20-day moving average (MA) of 16.98, below the 50-day MA of 19.85, and below the 200-day MA of 19.88, indicating a neutral trend. The MACD of -1.02 indicates Negative momentum. The RSI at 45.51 is Neutral, neither overbought nor oversold. The STOCH value of 88.68 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NAMS.

NewAmsterdam Pharma Company Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HRMY	77 Outperform	$1.70B	11.80	25.84%	―	22.80%	18.12%
ARQT	57 Neutral	$1.73B	―	-113.76%	―	229.74%	70.23%
Sector *	51 Neutral	$5.32B	3.41	-40.36%	2.89%	17.93%	2.52%
RXRX	51 Neutral	$2.30B	―	-61.89%	―	32.00%	-6.86%
NAMS	47 Neutral	$1.92B	―	-61.35%	―	―	―
DNLI	45 Neutral	$2.28B	―	-37.40%	―	-100.00%	-144.79%
MTSR	40 Underperform	$1.95B	―		―	―	―

NewAmsterdam Pharma Company Corporate Events

NewAmsterdam Pharma Appoints Adele Gulfo to Board

On April 15, 2025, NewAmsterdam Pharma appointed Adele Gulfo as an independent director to its Board of Directors, a strategic move as the company prepares for the potential launch of its drug obicetrapib next year. Gulfo’s extensive experience in pharmaceutical leadership and her history of successful drug launches are expected to significantly contribute to NewAmsterdam’s commercial strategy and infrastructure development, enhancing its position in the cardiovascular treatment market.

Spark’s Take on NAMS Stock

According to Spark, TipRanks’ AI Analyst, NAMS is a Neutral.

NewAmsterdam Pharma’s stock score reflects a challenging financial performance with ongoing operational losses typical of biotech firms. While the balance sheet is strong, the lack of profitability and negative cash flow remain concerns. Technical analysis indicates bearish sentiment, and valuation metrics are weak due to the negative P/E ratio and no dividend yield. However, significant corporate achievements in clinical trials provide a positive outlook for future growth and potential stock recovery.

To see Spark’s full report on NAMS stock, click here.